| 2011-03-14: |
R&D Productivity Measures Consistently Under - Scored and Under - Valued, EvaluatePharma Data Reveals
London ( PRN/ots ) - Pharmaceutical R&D productivity is consistently undercounted. Most reports fail to fully count the number of new drugs that reach the market, missing out on billions of dollars of sales generated by R&D investment, an analysis of EvaluatePharma data shows. Most counts (...) |
| 2011-03-18: |
Amgen Statement on CHMP Opinion on Vectibix( R ) ( Panitumumab ) Use With Chemotherapy in Metastatic Colorectal Cancer
Thousand Oaks, California ( PRN/ots ) - Amgen today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a negative opinion for Amgen's application to extend the marketing (...) |
| 2006-01-18: |
STMicroelectronics and Veredus Laboratories Team to Diagnose Avian Flu Using Rapid - Detection Point - of - Need Lab - on - Chip
Geneva and Singapore ( PRN/ots ) - STMicroelectronics ( NYSE: STM ) and Veredus Laboratories today announced that they are developing a fast, point - of - need diagnostic capability that will enable health practitioners to quickly detect strains of Avian Flu and other influenza viruses. The diagnostic capability, (...) |
| 2008-10-02: |
UNICEF and Pampers Announce Partnership Aimed at Eliminating Deadly Disease by 2012
Geneva ( PRN/ots ) - - Actress, Producer and Mother Salma Hayek Calls for Participation in Campaign to Eliminate Disease Responsible for the Death of one Newborn Baby Approximately Every Three Minutes A global review confirms that the elimination of maternal and newborn tetanus, preventable (...) |
| 2008-12-14: |
Xeloda Shows Strong Promise in Early Breast Cancer
San Antonio, Texas ( PRN/ots ) - - FOR NON - US DOMESTIC and NON - UK journalists only - Early Data Indicate Chemotherapy Pill Xeloda, Already Proven in Advanced Breast Cancer, May Also Reduce Recurrence of Early Breast Cancer Data presented today indicate that adding Xeloda (...) |
| 2010-07-12: |
Edoxaban Demonstrates Superior Efficacy Compared With Enoxaparin Sodium in Preventing VTE After Total Knee Replacement
Tokyo, July 12, 2010 ( PRN/ots ) - Daiichi Sankyo Company, Limited announced that its investigational once - daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior to enoxaparin in preventing venous thromboembolic ( VTE ) events in patients following total knee replacement ( TKR ), a type (...) |
| 2008-04-17: |
New Data Confirm Pramipexole ( Mirapexin( R )/Sifrol( R ) ) Can Significantly Reduce Sleep Disturbance for People With Restless Legs Syndrome ( RLS )
Ingelheim, Germany ( PRN/ots ) - - For Healthcare Media Outside the U.S.A. - Studies Demonstrate Positive and Rapid Impact of Pramipexole on the Core Symptoms of Restless Legs Syndrome and Sleep Disturbance A new study has shown that pramipexole ( Mirapexin( R )/Sifrol( R ) ) can significantly reduce (...) |
| 2008-06-25: |
First Comprehensive Report on Colorectal Cancer ( CRC ) Care in Europe and Australia Reveals Urgent Need for Action
London ( PRN/ots ) - - Few Countries Have Prioritised This Potentially Preventable and Curable Cancer The first cross - country report on the management and funding of colorectal cancer ( CRC ) reveals an urgent need for action to improve the survival of patients diagnosed with this (...) |
| 2007-11-16: |
Avastin Receives Positive Opinion in Europe for First - Line Treatment of Patients With Advanced Kidney Cancer
Basel, Switzerland, November 16 ( PRN/ots ) - - Avastin Offers Patients the Chance to Live Twice as Long Without Their Disease Advancing Roche announced today that the European Committee for Medicinal Products for Human Use ( CHMP ) has issued a positive recommendation for Avastin ( bevacizumab ) (...) |
| 2008-04-11: |
Status of the E2007 ( perampanel ) Development Program - Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications
Tokyo, Japan ( PRN/ots ) - E2007 ( perampanel ) is a first - in - class, orally administered, highly selective non - competitive AMPA - type glutamate receptor antagonist, in development by Eisai ( TSE:4523 ) for several indications, including Parkinson's disease, neuropathic pain, epilepsy, multiple sclerosis and migraine prophylaxis. The AMPA receptor (...) |
| 2007-06-02: |
New Data Show Bondronat( R ) Prevents Bone Loss Caused by anastrozole in Women With Surgically Treated Breast Cancer
Chicago, Illinois ( PRN/ots ) - - One Year Results From the ARIBON Study Presented at ASCO 2007 Bondronat( R ) ( ibandronic acid ) has been shown to prevent bone loss caused by anastrozole in post - menopausal women given adjuvant therapy for early breast cancer according to (...) |
| 2004-08-23: |
FDA Approves Zelnorm as the First Rx Therapy for Chronic Constipation
Basel, Switzerland ( PRN/ots ) - - 4.5 Million Americans Suffer from Constipation Most of the Time Novartis Pharma AG announced that the U.S. Food and Drug Administration ( FDA ) today approved a supplemental indication for its pro - motility agent Zelnorm( R ) ( tegaserod maleate ) for the (...) |
| 2007-05-07: |
Isotechnika Announces Interim Three Month Data From Phase 2b Kidney Transplant Trial
Edmonton, Alberta ( PRN/ots ) - Isotechnika Inc. today announced the audited three month results, reviewed by the Data Monitoring Committee, of the first third of the patients treated in its Phase 2b de novo kidney transplant trial for the Company's lead immunosuppressive drug, ISA247. This (...) |
| 2008-12-12: |
Agendia's MammaPrint( R ) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Huntington Beach, California and Amsterdam ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint( R )'s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura van 't Veer, from the Netherlands Cancer Institute, presented the data at the (...) |
| 2008-05-13: |
XIENCE( TM ) V Drug Eluting Stent from Abbott Outperforms Market - Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Barcelona, Spain ( PRN/ots ) - - Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long - Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients Treated with TAXUS Long - term data presented for the first time today from the SPIRIT III (...) |
| 2006-10-31: |
New Survey Reveals Startling Ignorance About Europe's Number One Cancer Killer - Lung Cancer
Basel, Switzerland ( PRN/ots ) - Seventy percent of European patients battling lung cancer had never regarded the disease as a threat prior to learning of their condition, according to results from a new pan - European public and patient survey announced on the eve of Lung (...) |
| 2009-12-22: |
Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Calgary, Canada ( PRN/ots ) - Resverlogix Corp. ( "Resverlogix" or the "Company" ) announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX - 208, Resverlogix's oral small molecule therapy for the treatment of (...) |
| 2006-10-02: |
Isotechnika Receives Approval From the German Competent Authority for a Pivotal Phase III Psoriasis Clinical Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. announced today that the Company received approval from the German Competent Authority to conduct a pivotal Phase III clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247. The Phase III European/ (...) |
| 2004-11-30: |
Unique Cancer Drug Avastin Now Shown to Improve Survival Across Different Metastatic Colorectal Cancer Regimens
Basel, Switzerland, November 30 ( PRN/ots ) - Roche and Genentech, Inc., announced today that Avastin( TM ) ( bevacizumab, rhuMAb - VEGF ), a new innovative anti - angiogenesis drug, has shown for the first time that it significantly increases survival in patients with metastatic colorectal cancer when used in combination (...) |
| 2009-08-27: |
Wyeth's Torisel Approved by European Commission for the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma
Maidenhead, England ( PRN/ots ) - Wyeth Europa Ltd., a division of Wyeth ( NYSE: WYE ), announced today that the European Commission has approved the mTOR ( mammalian target of rapamycin ) inhibitor TORISEL( R ) ( temsirolimus ) for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (...) |
| 2004-10-22: |
Avastin Receives Positive Opinion in Europe for the Treatment of Patients with Metastatic Colorectal Cancer
Basel, Switzerland ( PRN/ots ) - Roche announced today that its innovative cancer drug, Avastin has received a positive recommendation from the European Committee for Medicinal Products for Human Use ( CHMP ). The CHMP has recommended that Avastin ( bevacizumab ) in combination with intravenous 5 - fluorouracil/folinic acid (...)
References: 1. Hurwitz, H, Fehrenbacher, L, Novotny, W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. New England Journal of Medicine 2004; 350( 23 ): 2335 - 2342 2. J. Ferlay, F. Bray, P. Pisani and D.M. Parkin. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. Lyon, IARCPress, 2001 For further information: Cancer: www.health - kiosk.com - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - * Bolus 5 - FU/Leucovorin/irinotecan ( also known as the Saltz regimen )
ots Originaltext: Roche Pharmaceuticals Im Internet recherchierbar: http://www.presseportal.de Contact: Media Relations Contacts Phone: +41 - 61 - 688 - 88 - 88 / e - mail: basel.mediaoffice@roche.com, - Baschi Durr, - Alexander Klauser, - Daniel Piller ( Head Roche Group Media Office ), - Katja Prowald ( Head Science Communications ), - Martina Rupp |
| 2007-07-23: |
International Experts and Women Living With HIV Discuss Urgent Needs of HIV - Positive Women at International AIDS Society ( IAS ) Congress
Sydney, Australia ( PRN/ots ) - - Panelists Available For Interviews - For Immediate Release: Webcast Will Be Available At: Http://Link.Viostream.Com/?A02deceb - Ecf4 - 4d9f - 9118 - F5f60faef629 Women Living Positive, a roundtable discussion at the IAS congress in Sydney, featured the perspectives of (...) |
| 2008-04-26: |
Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C
Basel, Switzerland ( PRN/ots ) - - Roche Also Provides Comment on Results of "IDEAL" Trial Roche today announced that compelling new data from three studies indicate that chronic hepatitis C patients who received PEGASYS( R ) ( peginterferon alfa - 2a ) plus COPEGUS( R ) ( ribavirin ) had a greater chance (...) |
| 2005-11-14: |
Fournier Pharma Announces Results of the Largest Clinical Trial in Patients With Type 2 Diabetes Demonstrating Positive Effects of Fenofibrate Therapy on Cardiovascular Events
Dallas, Texas, November 14 ( PRN/ots ) - - FIELD Confirms Fenofibrate Produces Macrovascular and Microvascular Benefits in Diabetic Patients Without Previous Cardiovascular Disease Although Primary Endpoint is not met Results of the largest intervention study ever conducted for the prevention of cardiovascular disease in (...) |
| 2007-06-15: |
Inovelon( R ) A New Treatment for Lennox - Gastaut Syndrome Launched in Europe
London ( PRN/ots ) - - First Treatment Licensed Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, ( Headquarters: London, President Yutaka Tsuchiya ) today announced the launch in Germany and Scandinavia of its new anti - epileptic agent Inovelon ( rufinamide ) indicated for adjunctive (...) |
| 2008-06-12: |
New Data Demonstrates Joint Damage is Inhibited With Wyeth's Biologic Enbrel( R ) Plus Methotrexate in Patients With Early Active Rheumatoid Arthritis
Maidenhead, England ( PRN/ots ) - - Study Results Provide Further Evidence That Early Treatment of Rheumatoid Arthritis With Enbrel( R ) Plus Methotrexate in Moderate to Severe Patients can Stop the Disease From Progressing, and Helps Patients Return to More Normal and Productive Lives Data presented (...) |
| 2007-10-31: |
Breaking News About Treatment of World's Leading Cause of Adult Blindness to be Published Next Week
Brussels ( PRN/ots ) - First study to investigate the protective effect of a lipid - lowering agent on diabetic eye disease to be published on - line in Lancet, Tuesday, 6th November 2007 Diabetic eye disease ( called diabetic retinopathy ) is the leading cause of vision loss (...) |
| 2005-05-24: |
BioWa and Medarex Announce Expansion of Licensing Agreement for BioWa's Potelligent( TM ) Technology
Princeton, New Jersey ( PRN/ots ) - - BioWa Grants the Second Potelligent( TM ) Antibody Technology License to Medarex BioWa, Inc. and Medarex, Inc. ( Nasdaq: MEDX ) today announced that BioWa has granted a second license to Medarex to use BioWa's Potelligent( TM ) Technology for the enhancement of (...) |
| 2007-03-09: |
Vital Images Features 'The Vital Community' at the 2007 European Congress of Radiology ( ECR ) Conference
Den Haag, Netherlands ( PRN/ots ) - - The ViTAL Community highlights relationships empowered by comprehensive enterprise - wide advanced visualization and analysis solutions, education and services Vital Images Europe, B.V. a leading provider of enterprise - wide advanced visualization and analysis solutions, will showcase 'the ViTAL Community' (...) |
| 2008-06-03: |
Isotechnika to Hold Conference Call to Discuss Positive PROMISE Trial
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. will hold a conference call to discuss final Phase 2b PROMISE kidney transplant data for the Company's lead immunosuppressive drug, voclosporin, on Wednesday, June 4th at 9:00 a.m. ET/7:00 a.m. MT. As previously announced, (...) |
| 2005-08-02: |
Lundbeck Selects MCI to Provide a Fully - Managed Worldwide Network
Copenhagen, Denmark ( PRN/ots ) - - International pharmaceutical Company Chooses MCI Private IP, IP Dedicated and Colocation to Link 58 Sites Across Europe, Asia and North and South America MCI, Inc. ( Nasdaq: MCIP ) today announced that the international pharmaceutical company H. Lundbeck A/S (...) |
| 2009-09-01: |
Edoxaban - next generation oral anticoagulant under investigation to help prevent stroke in patients with atrial fibrillation
Barcelona ( na Originaltextservice ) - New treatment could offer further option in addition to current standard of care in thromboembolic disease Edoxaban, an oral factor Xa inhibitor, is currently being investigated in the pivotal phase III study ENGAGE AF - TIMI 48 ( Effective aNticoaGulation (...) |
| 2007-09-26: |
New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid - Induced Bowel Dysfunction in Patients With Chronic Severe Pain
Cambridge, England ( PRN/ots ) - - New Approach in the Development of Opioid - Based Pain Management Therapy Improves Bowel Function The oral prolonged - release ( PR ) oxycodone / naloxone combination tablet reduces opioid - induced bowel dysfunction in patients with chronic severe pain compared to treatment with (...) |
| 2004-10-19: |
Men with Erectile Dysfunction Cite Reduction in Time Pressure to Perform and Increased Sexual Self - Confidence As Preference Points for Cialis
Buenos Aires, Argentina ( PRN/ots ) - - - Additional Analysis Shows Couples Agree Cialis Improves Erectile Function in Men with ED and Increases Satisfaction with Sexual Experience - - An international study conducted in 21 countries showed that 82 percent of men with ED who were (...) |
| 2008-09-24: |
Landmark UPLIFT Study Reaffirms the Safety of Spiriva ( tiotropium ) in Patients With Chronic Obstructive Pulmonary Disease
Leuven, Belgium ( PRN/ots ) - - For Media Outside US and Canada - Prof. dr. Marc Decramer, Head of Pneumology of the University Hospitals Leuven, is Lead Investigator of the International UPLIFT Study Investigating Treatment of COPD Patients With tiotropium. Today he Elaborates on the (...) |
| 2010-08-05: |
Agendia Inaugurates New State - of - the - Art Genomics Laboratory in Irvine
Irvine, California, and Amsterdam, August 5, 2010 ( PRN/ots ) - Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state - of - the - art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington (...) |
| 2006-09-12: |
Exubera Hailed as Innovation In Prestigious European and American Awards
New York ( PRN/ots ) - - WSJ/Professor Pedro Nueno: "The drug could encourage diabetes sufferers to get treatment earlier and more often. This has such a tremendous advantage for a huge number of people worldwide. It is a real breakthrough." - PharmaBarometer: "Despite only (...) |
| 2006-09-03: |
New Study Shows Benefits of Coversyl ( R ) ( Perindopril ) in Elderly With Chronic Heart Failure
Barcelona, Spain ( PRN/ots ) - - Coversyl( R ) in PEP - CHF Trial, is the First Agent to Demonstrate Clinical Benefits in Elderly Heart Failure Patients With Diastolic Dysfunction The ACE inhibitor Coversyl( R ) ( perindopril ) provides a number of clinical benefits to elderly people with chronic heart (...) |
| 2007-11-05: |
Mircera( R ) Shown to be Effective Anaemia Treatment for Renal Patients With Low Haemoglobin Levels
Basel, Switzerland, November 5 ( PRN/ots ) - - Low Haemoglobin Levels Associated With Increased Risk of Cardiovascular Disease and Death Data from the analysis of six major trials for the innovative new renal anaemia treatment MIRCERA, have shown that it effectively corrects and maintains (...) |
| 2008-10-24: |
GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
Paris ( PRN/ots ) - - GenOdyssee Has Received Notice of Allowance of European Patent Application Covering Its Core Natural Evolution Technology Invented in 2002, and Received Broad Product Applications Protection Rights to All Cytokine Families GenOdyssee ( GO ), a biotechnology company dedicated to the discovery and (...) |
| 2011-04-04: |
Eppendorf licenses technology for thermal cyclers to Labnet International
Hamburg ( na Originaltextservice ) - Eppendorf AG has licensed patents covering gradient technology for thermal cyclers to Labnet International for their Labnet® Multigene gradient Thermal Cyclers, including US patent Nos. 6,767,512 and 7,074,367. Eppendorf utilizes the technology in its Eppendorf Mastercycler® pro gradient, Mastercycler (...) |
| 2006-07-26: |
Media Reminder - Journalism Awards for Lung Cancer Reporting
London ( PRN/ots ) - The Tempus Journalism Awards, launched earlier this year by the Global Lung Cancer Coalition ( GLCC ), is the first global initiative to recognise excellence in lung cancer reporting. There are still two months remaining before judging begins - so please continue to send (...) |
| 2010-06-28: |
Kowa Company, Ltd. Grants Abbott Exclusive Rights to Market Pitavastatin Calcium, a Lipid - lowering Drug, in Australia and New Zealand
Wokingham, England, June 28, 2010 ( PRN/ots ) - Following an enthusiastic expansion programme into new markets, Kowa Company, Ltd. ( President: Yoshihiro Miwa ), headquartered in Nagoya, Japan, has granted Abbott, headquartered in Illinois, USA the exclusive license to distribute and market pitavastatin calcium ( brand name Livalo ), (...) |
| 2006-12-14: |
Germany Qualifies Gemalto for World's Largest Microprocessor Card - Based Healthcare Initiative
Amsterdam, The Netherlands ( PRN/ots ) - - In Germany, 80 Million Patient Cards Will be Renewed Over the Next 5 Years Gemalto ( Euronext NL0000400653 GTO ), a world leader in digital security, today announces it is taking part in Germany's first healthcare pilot program based (...) |
| 2005-11-16: |
Preliminary Results of Ongoing Phase II Study Show Early Promise With ZD6474 ( ZACTIMA[TM] ) in a Rare Form of Thyroid Cancer
Alderley Park, England, November 16 ( PRN/ots ) - - New Data Add Momentum to AstraZeneca's Novel Oncology Drug, ZD6474 ( ZACTIMA[TM] ), Which has Already Shown Promising Data in Non - Small Cell Lung Cancer ( NSCLC ) Preliminary results from a Phase II study showing (...) |
| 2008-05-29: |
Movetis Files RESOLOR( R ) With EMEA for the Indication of Chronic Constipation
Turnhout, Belgium ( PRN/ots ) - Movetis today announced that the European Medicines Agency ( EMeA ) has accepted the Marketing Authorization Application ( MAA ) submission for RESOLOR( R ) ( prucalopride ) as a treatment for chronic constipation in adults in whom laxatives fail to provide adequate relief. RESOLOR is a new (...) |
| 2004-12-09: |
Baxter Suspends Enrollment in European Clinical Trial for PreFluCel
Deerfield, Illinois ( PRN/ots ) - Baxter International Inc. ( NYSE: BAX ) announced today that it has voluntarily suspended enrollment in the Phase II/III clinical study currently underway in Europe of its PreFluCel influenza vaccine, due to a higher than expected rate of mild fever and (...) |
| 2005-06-29: |
Global Survey Reveals Personal Impact of Bipolar Disorder
Vienna, Austria ( PRN/ots ) - - World Federation for Mental Health urges better understanding, treatment and management to improve outcomes for people living with bipolar disorder The World Federation for Mental Health ( WFMH ) today announced results of a global bipolar disorder consumer survey, Thinking Ahead, (...) |
| 2008-06-03: |
New Abbott Aluvia( R ) Tablet for Treatment of HIV Available in South Africa
Johannesburg, South Africa ( PRN/ots ) - - More than 5 Million South Africans Living with HIV Gain Access to First and Only Co - formulated, Non - refrigerated Protease Inhibitor Abbott ( NYSE: ABT ) today announced that the new tablet formulation of its protease inhibitor Aluvia( R ) ( lopinavir/ (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
